Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors

Cancer Science

Volumn 106, Issue 10, 2015, Pages 1438-1447

  Yu, Man ^a   Lee, Carol ^a   Wang, Marina ^a   Tannock, Ian F ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Doxorubicin; Drug distribution; Lansoprazole; Pharmacodynamic markers; Solid tumor

Indexed keywords

CASPASE 3; CASPASE 6; DOXORUBICIN; HISTONE H2AX; HISTONE H2AX GAMMA; LANSOPRAZOLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; PROTON PUMP INHIBITOR; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TUMOR LEVEL; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR CELL CULTURE; ANIMAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; MAMMARY NEOPLASMS, ANIMAL; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; LANSOPRAZOLE; MAMMARY NEOPLASMS, ANIMAL; MCF-7 CELLS; MICE; MICE, NUDE; PROTON PUMP INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945424858     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12756     Document Type: Article

References (50)

1. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013; 85: 1219-26.
2. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
3. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11: 8782-8.
4. Patel KJ, Tredan O, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol 2013; 72: 127-38.
5. Saggar JK, Fung AS, Patel KJ, Tannock IF. Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Mol Cancer Ther 2013a; 12: 542-52.
6. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54.
7. Saggar JK, Yu M, Tan Q, Tannock IF. The tumor microenvironment and strategies to improve drug distribution. Front Oncol 2013; 3: 154.
8. Saggar JK, Tannock IF. Chemotherapy rescues hypoxic tumor cells and induces their reoxygenation and repopulation - an effect that is inhibited by the hypoxia-activated pro-drug TH-302. Clin Cancer Res 2015; 21: 2107-14.
9. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101: 937-49.
10. Manallack DT. The pK(a) distribution of drugs: application to drug discovery. Perspect Medicin Chem 2007; 1: 25-38.
11. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000; 85: 217-29.
12. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 2007; 67: 10627-30.
13. Schempp CM, von Schwarzenberg K, Schreiner L et al. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Ther 2014; 13: 926-37.
14. Hernandez A, Serrano-Bueno G, Perez-Castineira JR, Serrano A. Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer. Curr Pharm Des 2012; 18: 1383-94.
15. Sabolic I, Brown D, Verbavatz JM, Kleinman J. H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am J Physiol 1994; 266(6 Pt 2): F868-77.
16. De Milito A, Marino ML, Fais S. A rationale for the use of proton pump inhibitors as antineoplastic agents. Curr Pharm Des 2012; 18: 1395-406.
17. Duffy A, Le J, Sausville E, Emadi A. Autophagy modulation: a target for cancer treatment development. Cancer Chemother Pharmacol 2015; 75: 439-47.
18. Tan Q, Joshua A, Saggar J et al. Effects of pantoprazole to enhance activity of docetaxel against human tumor xenografts by inhibiting autophagy. Br J Cancer, 2015; 112: 832-40.
19. Levy JM, Thompson JC, Griesinger AM et al. Autophagy inhibition improves chemosensitivity in BRAFV600E brain tumors. Cancer Discov 2014; 4: 773-80.
20. Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem 2014; 289: 17163-73.
21. Yang M, Zeng P, Kang R et al. S100A8 contributes to drug resistance by promoting autophagy in leukemia cells. PLoS ONE 2014; 9: e97242.
22. Patel KJ, Lee C, Tan Q, Tannock IF. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res 2013; 19: 6766-76.
23. Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 2006; 94: 863-9.
24. Luciani F, Spada M, De Milito A et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96: 1702-13.
25. Ferrari S, Perut F, Fagioli F et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med 2013; 11: 268.
26. Tunggal JK, Cowan DS, Shaikh H, Tannock IF. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 1999; 5: 1583-6.
27. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357-60.
28. Fung AS, Jonkman J, Tannock IF. Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. Neoplasia 2012; 14: 324-34.
29. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8: 878-84.
30. Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev 2014; 33: 1095-108.
31. Parolini I, Federici C, Raggi C et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009; 284: 34211-22.
32. Federici C, Petrucci F, Caimi S et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS ONE 2014; 9: e88193.
33. Honscheid P, Datta K, Muders MH. Autophagy: detection, regulation and its role in cancer and therapy response. Int J Radiat Biol 2014; 90: 628-35.
34. Marino ML, Pellegrini P, Di Lernia G et al. Autophagy is a protective mechanism for human melanoma cells under acidic stress. J Biol Chem 2012; 287: 30664-76.
35. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 2010; 267: 515-25.
36. Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett 2015; 356(2 Pt B): 697-703.
37. De Milito A, Iessi E, Logozzi M et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007; 67: 5408-17.
38. De Milito A, Canese R, Marino ML et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010; 127: 207-19.
39. Zhang B, Yang Y, Shi X et al. Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. Cancer Lett 356; 2(2 Pt B): 704-12.
40. Zhang S, Wang Y, Li SJ. Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochem Biophys Res Commun 2014; 448: 424-9.
41. Spugnini EP, Baldi A, Buglioni S et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011; 9: 221.
42. Spugnini EP, Buglioni S, Carocci F et al. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014; 12: 225.
43. Papagerakis S, Bellile E, Peterson LA et al. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila) 2014; 7: 1258-69.
44. Chen M, Huang SL, Zhang XQ et al. Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 2012; 113: 2474-87.
45. Udelnow A, Kreyes A, Ellinger S et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS ONE 2011; 6: e20143.
46. Marino ML, Fais S, Djavaheri-Mergny M et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis 2010; 1: e87.
47. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935-51.
48. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013; 19: 25-35.
49. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-29.
50. Brana I, Ocana A, Chen EX et al. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs 2014; 32: 1269-77.